BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) used to treat peritoneal surface disease (PSD) from appendiceal cancer have shown variability in survival outcomes. The primary goal of this study was to determine predictors of surgical morbidity and overall survival. The secondary goal was to describe the impact of nodal status on survival after CRS/HIPEC for PSD from low-grade appendiceal (LGA) and high-grade appendiceal (HGA) primary lesions. METHODS: A retrospective analysis of 1,069 procedures from a prospective database was performed. Patient characteristics, tumor grade, nodal status, performance status, resection status, morbidity, mortality, and survival were reviewed. RESULTS: The study identified 481 CRS/HIPEC procedures: 317 (77.3 %) for LGA and 93 (22.7 %) for HGA lesions. The median follow-up period was 44.4 months, and the 30-day major morbidity and mortality rates were respectively 27.8 and 2.7 %. Major morbidity was jointly predicted by incomplete cytoreduction (p = 0.0037), involved nodes (p < 0.0001), and comorbidities (p = 0.003). Multivariate negative predictors of survival included positive nodal status (p = 0.003), incomplete cytoreduction (p < 0.0001), and preoperative chemotherapy (p = 0.04) in LGA patients and incomplete cytoreduction (p = 0.0003) and preoperative chemotherapy (p = 0.0064) in HGA patients. After complete cytoreduction, median survival was worse for patients with positive nodes than for those with negative nodes in LGA (85 months vs not reached [82 % alive at 90 months]; p = 0.002) and HGA (30 vs 153 months; p < 0.0001). CONCLUSIONS: Positive nodes are associated with decreased survival not only for HGA patients but also for LGA patients even after complete cytoreduction. Nodal status further stratifies histologic grade as a prognostic indicator of survival. Patients with node-negative HGA primary lesions who receive a complete cytoreduction may experience survival comparable with that for LGA patients.
BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) used to treat peritoneal surface disease (PSD) from appendiceal cancer have shown variability in survival outcomes. The primary goal of this study was to determine predictors of surgical morbidity and overall survival. The secondary goal was to describe the impact of nodal status on survival after CRS/HIPEC for PSD from low-grade appendiceal (LGA) and high-grade appendiceal (HGA) primary lesions. METHODS: A retrospective analysis of 1,069 procedures from a prospective database was performed. Patient characteristics, tumor grade, nodal status, performance status, resection status, morbidity, mortality, and survival were reviewed. RESULTS: The study identified 481 CRS/HIPEC procedures: 317 (77.3 %) for LGA and 93 (22.7 %) for HGA lesions. The median follow-up period was 44.4 months, and the 30-day major morbidity and mortality rates were respectively 27.8 and 2.7 %. Major morbidity was jointly predicted by incomplete cytoreduction (p = 0.0037), involved nodes (p < 0.0001), and comorbidities (p = 0.003). Multivariate negative predictors of survival included positive nodal status (p = 0.003), incomplete cytoreduction (p < 0.0001), and preoperative chemotherapy (p = 0.04) in LGA patients and incomplete cytoreduction (p = 0.0003) and preoperative chemotherapy (p = 0.0064) in HGA patients. After complete cytoreduction, median survival was worse for patients with positive nodes than for those with negative nodes in LGA (85 months vs not reached [82 % alive at 90 months]; p = 0.002) and HGA (30 vs 153 months; p < 0.0001). CONCLUSIONS: Positive nodes are associated with decreased survival not only for HGA patients but also for LGA patients even after complete cytoreduction. Nodal status further stratifies histologic grade as a prognostic indicator of survival. Patients with node-negative HGA primary lesions who receive a complete cytoreduction may experience survival comparable with that for LGA patients.
Authors: Hatem El Halabi; Vadim Gushchin; Jennifer Francis; Nicholas Athas; Ryan Macdonald; Carol Nieroda; Kimberly Studeman; Armando Sardi Journal: Ann Surg Oncol Date: 2011-06-24 Impact factor: 5.344
Authors: Hatem El Halabi; Vadim Gushchin; Jennifer Francis; Nicholas Athas; Ryan Macdonald; Carol Nieroda; Kimberly Studeman; Armando Sardi Journal: Ann Surg Oncol Date: 2011-07-12 Impact factor: 5.344
Authors: Terence C Chua; Brendan J Moran; Paul H Sugarbaker; Edward A Levine; Olivier Glehen; François N Gilly; Dario Baratti; Marcello Deraco; Dominique Elias; Armando Sardi; Winston Liauw; Tristan D Yan; Pedro Barrios; Alberto Gómez Portilla; Ignace H J T de Hingh; Wim P Ceelen; Joerg O Pelz; Pompiliu Piso; Santiago González-Moreno; Kurt Van Der Speeten; David L Morris Journal: J Clin Oncol Date: 2012-05-21 Impact factor: 44.544
Authors: Robert F Bradley; John H Stewart; Gregory B Russell; Edward A Levine; Kim R Geisinger Journal: Am J Surg Pathol Date: 2006-05 Impact factor: 6.394
Authors: John H Stewart; Perry Shen; Gregory B Russell; Robert F Bradley; Jonathan C Hundley; Brian L Loggie; Kim R Geisinger; Edward A Levine Journal: Ann Surg Oncol Date: 2006-03-14 Impact factor: 5.344
Authors: Edward A Levine; John H Stewart; Gregory B Russell; Kim R Geisinger; Brian L Loggie; Perry Shen Journal: J Am Coll Surg Date: 2007-05 Impact factor: 6.113
Authors: Edward A Levine; Konstantinos I Votanopoulos; Shadi A Qasem; John Philip; Kathleen A Cummins; Jeff W Chou; Jimmy Ruiz; Ralph D'Agostino; Perry Shen; Lance D Miller Journal: J Am Coll Surg Date: 2015-12-21 Impact factor: 6.113
Authors: Jing Su; Guangxu Jin; Konstantinos I Votanopoulos; Lou Craddock; Perry Shen; Jeff W Chou; Shadi Qasem; Stacey S O'Neill; Kathleen Cummins Perry; Lance D Miller; Edward A Levine Journal: Ann Surg Oncol Date: 2020-01-24 Impact factor: 5.344
Authors: Konstantinos I Votanopoulos; Andrea Mazzocchi; Hemamylammal Sivakumar; Steven Forsythe; Julio Aleman; Edward A Levine; Aleksander Skardal Journal: Ann Surg Oncol Date: 2018-11-09 Impact factor: 5.344
Authors: Konstantinos Ioannis Votanopoulos; David Bartlett; Brendan Moran; Choudry M Haroon; Greg Russell; James F Pingpank; Lekshmi Ramalingam; Chandrakumaran Kandiah; Konstantinos Chouliaras; Perry Shen; Edward A Levine Journal: Ann Surg Oncol Date: 2017-12-29 Impact factor: 5.344
Authors: Omeed Moaven; Konstantinos I Votanopoulos; Perry Shen; Paul Mansfield; David L Bartlett; Greg Russell; Richard McQuellon; John H Stewart; Edward A Levine Journal: Ann Surg Oncol Date: 2019-11-12 Impact factor: 5.344
Authors: Harveshp D Mogal; Edward A Levine; Greg Russell; Perry Shen; John H Stewart; Konstantinos I Votanopoulos Journal: Ann Surg Oncol Date: 2015-08-20 Impact factor: 5.344
Authors: Harveshp D Mogal; Edward A Levine; Nora F Fino; Chukwuemeka Obiora; Perry Shen; John H Stewart; Konstantinos I Votanopoulos Journal: Ann Surg Oncol Date: 2015-11-16 Impact factor: 5.344
Authors: Kathleen A Cummins; Gregory B Russell; Konstantinos I Votanopoulos; Perry Shen; John H Stewart; Edward A Levine Journal: J Gastrointest Oncol Date: 2016-02